(5-氯-2-羟基苯基)硼酸 | 398475-42-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (5-氯-2-羟基苯基)硼酸
• 中文别名: [2-(1,3-二恶烷-2-基)苯基]甲醇
• 英文名称: [2-(1,3-Dioxan-2-yl)phenyl]methanol
• CAS: 398475-42-8
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: YJXIDTKPQFMUCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 1,4-dihydropyridine compounds as bradykinin antagonists
  申请人：——

  公开号：US20020161006A1

  公开（公告）日：2002-10-31

  The present invention relates to compounds of the formula 1 wherein each A is independently halo; Y is —(CH 2 ) m —, —C(O)— or —S(O)—; R 1 and R 2 are independently C 1-4 alkyl; R 3 is substituted azacycloalkyl etc.; R 4 is phenyl substituted at the 2-position with a substituent selected from substituted C 1-7 alkyl, substituted C 1-7 alkoxy, amine, etc; R 5 is hydrogen or C 1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.

  本发明涉及公式1的化合物，其中每个A独立地是卤素；Y是—（CH2）m—，—C（O）—或—S（O）—；R1和R2独立地是C1-4烷基；R3是取代的氮杂环烷基等；R4是苯基，在2位被取代，取代基为取代的C1-7烷基，取代的C1-7烷氧基，胺等；R5是氢或C1-4烷基；m为0、1或2；n为0、1、2、3、4或5。本发明还涉及包含这些化合物的制药组合物以及在治疗和预防炎症、哮喘、过敏性鼻炎、疼痛和其他疾病中使用这些化合物的用途。
• 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS
  申请人：PFIZER PHARMACEUTICALS INC.

  公开号：EP1307449A1

  公开（公告）日：2003-05-07
• TEXTILSCHONENDENDES TEXTILREINIGUNGSMITTEL
  申请人：Henkel Kommanditgesellschaft auf Aktien

  公开号：EP1492863A1

  公开（公告）日：2005-01-05
• US6653313B2
  申请人：——

  公开号：US6653313B2

  公开（公告）日：2003-11-25
• [EN] 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS<br/>[FR] 1,4-DIHYDROPYRIDINES UTILISES COMME ANTAGONISTES DE LA BRADYKININE
  申请人：PFIZER PHARMA

  公开号：WO2002012235A1

  公开（公告）日：2002-02-14

  The present invention relates to compounds of formula (I) wherein each A is independently halo; Y is (CH2)m-, -C(O)- or S(O)-; R?1 and R2¿ are independently C¿1-4? alkyl; R?3¿ is substituted azacycloalkyl etc.; R4 is phenyl substituted at the 2-position with a substituent selected from substituted C¿1-7? alkyl, substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R?5¿ is hydrogen or C¿1-4? alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.